sur DocMorris AG (isin : CH0042615283)
DocMorris Meets 2024 Goals, Projects Significant Growth for 2025
DocMorris AG has announced it achieved its financial targets for 2024, with a notable focus on electronic prescriptions in Germany. This has led to a steady climb in prescription drug revenues. The non-prescription sector also posted profitable results. Notably, the TeleClinic subsidiary doubled its revenue.
In 2025, DocMorris anticipates a 50% growth in prescription drug sales in the first quarter. To support its strategic objectives, including customer acquisition, the company is planning a capital increase of around CHF 200 million.
In their environmental efforts, DocMorris reported a 67% reduction in CO2 emissions after switching to climate-neutral electricity. The company remains committed to pursuing net-zero emissions.
The organization recently closed its Halle site and streamlined operations which contributed to these achievements. Additionally, DocMorris is preparing to launch new apps aimed at enhancing customer accessibility throughout 2025.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de DocMorris AG